<![CDATA[Embla Medical — December 2024]]>Godmorgen 🙂

]]>https://dev.proinvestor.com/forum/topic/401340/embla-medical-december-2024RSS for NodeSat, 06 Jun 2026 05:02:56 GMTSun, 01 Dec 2024 05:58:56 GMT60<![CDATA[Reply to Embla Medical — December 2024 on Tue, 17 Dec 2024 12:51:51 GMT]]>Modstanden i 36-37 området er meget markant. Aktien bliver holdt i et skruestik i dette niveau. Det virker temmelig påfaldende.

]]>https://dev.proinvestor.com/forum/post/8056381https://dev.proinvestor.com/forum/post/8056381Tue, 17 Dec 2024 12:51:51 GMT<![CDATA[Reply to Embla Medical — December 2024 on Wed, 11 Dec 2024 04:14:25 GMT]]>Embla i Mio-klubben https://www.euroinvestor.dk/podcast/millionaerklubben-10

]]>https://dev.proinvestor.com/forum/post/8056382https://dev.proinvestor.com/forum/post/8056382Wed, 11 Dec 2024 04:14:25 GMT<![CDATA[Reply to Embla Medical — December 2024 on Tue, 10 Dec 2024 13:03:53 GMT]]>Tak for analyse. De kommende dage får vi at se om hvorvidt sælgerne fortsat er på banen omkring modstandsniveauet i 36-37 området.

]]>https://dev.proinvestor.com/forum/post/8056384https://dev.proinvestor.com/forum/post/8056384Tue, 10 Dec 2024 13:03:53 GMT<![CDATA[Reply to Embla Medical — December 2024 on Tue, 10 Dec 2024 06:37:11 GMT]]>Rapporten fra Intron Health kan læses her: https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/123391_241211_Embla_Medical_Initiation_Stepping_into_the_Future.pdf

]]>https://dev.proinvestor.com/forum/post/8056379https://dev.proinvestor.com/forum/post/8056379Tue, 10 Dec 2024 06:37:11 GMT<![CDATA[Reply to Embla Medical — December 2024 on Tue, 10 Dec 2024 06:12:21 GMT]]>Embla Medical får indledt dækning med "køb" af Intron Health
i dag kl. 07:47 ∙ MarketWire

Embla Medical

Embla Medical, der tidligere var kendt under navnet Össur, har fået indledt sin dækning med anbefalingen "køb" af finanshuset Intron Health.

Kursmålet for det islandske proteseselskab sættes i samme ombæring til 56 kr., skriver Bloomberg News.

Aktien steg mandag med 2,5 pct. til 36,90 kr., efter at Nordea løftede sit kursmål for aktien til 43,20 kr. fra 41 kr.

.\˙ MarketWire

]]>https://dev.proinvestor.com/forum/post/8056377https://dev.proinvestor.com/forum/post/8056377Tue, 10 Dec 2024 06:12:21 GMT<![CDATA[Reply to Embla Medical — December 2024 on Mon, 09 Dec 2024 11:55:32 GMT]]>Der bliver lige som tidligere hældt masse af aktier i niveauet 36-37. På et et tidspunkt må sælgerne nok løbe tør for aktier.

]]>https://dev.proinvestor.com/forum/post/8056383https://dev.proinvestor.com/forum/post/8056383Mon, 09 Dec 2024 11:55:32 GMT<![CDATA[Reply to Embla Medical — December 2024 on Mon, 09 Dec 2024 11:37:09 GMT]]>Buy: Valuation still not demanding, in our view, despite solid run
While the share is up 35% YTD, this on a par with EPS growth. Hence, it still
trades at the low end of its historical 10-year multiple range".

]]>https://dev.proinvestor.com/forum/post/8056376https://dev.proinvestor.com/forum/post/8056376Mon, 09 Dec 2024 11:37:09 GMT<![CDATA[Reply to Embla Medical — December 2024 on Mon, 09 Dec 2024 11:35:57 GMT]]>Plus the call highlighted that
Fior & Gentz provides highly personalised treatment, and thanks to its unique
configurator the company offers ~500,000 potential configurations. This,
combined with the sales synergies, makes us believe that Fior & Gentz is well
positioned to win market shares.

]]>https://dev.proinvestor.com/forum/post/8056378https://dev.proinvestor.com/forum/post/8056378Mon, 09 Dec 2024 11:35:57 GMT<![CDATA[Reply to Embla Medical — December 2024 on Mon, 09 Dec 2024 11:35:04 GMT]]>"Low penetration and attractive competitive situation
With the penetration rate of high-function orthoses being well below 5% in
developed markets, we see ample headroom for growth. The key competitor is
Ottobock while other companies mainly target low-function products, creating
an attractive duopolistic situation, in our view.

]]>https://dev.proinvestor.com/forum/post/8056371https://dev.proinvestor.com/forum/post/8056371Mon, 09 Dec 2024 11:35:04 GMT<![CDATA[Reply to Embla Medical — December 2024 on Mon, 09 Dec 2024 11:33:44 GMT]]>Nordea d. 9/12-2024: Target price
DKK 44.00

]]>https://dev.proinvestor.com/forum/post/8056374https://dev.proinvestor.com/forum/post/8056374Mon, 09 Dec 2024 11:33:44 GMT<![CDATA[Reply to Embla Medical — December 2024 on Mon, 09 Dec 2024 11:30:35 GMT]]>Prøv at kigge denne webcast igennem ved lejlighed. Det er en øjenåbner for hvad Emblas ortoser kan for mennesker med paralyseret lemmer som følge af blodprop, sklerose mv. De får mobiliteten tilbage.
https://media.ossur.com/video/upload/v1733508464/documents/corporate/presentations/Embla Medical - Neuro Orthotics (Fior and Gentz) - Virtual Group Call - 03.12.2024.mp4

]]>https://dev.proinvestor.com/forum/post/8056380https://dev.proinvestor.com/forum/post/8056380Mon, 09 Dec 2024 11:30:35 GMT<![CDATA[Reply to Embla Medical — December 2024 on Fri, 06 Dec 2024 13:02:27 GMT]]>Embla Medical: Financial Calendar 2025 https://mb.cision.com/Main/18404/4076816/3156011.pdf

]]>https://dev.proinvestor.com/forum/post/8056375https://dev.proinvestor.com/forum/post/8056375Fri, 06 Dec 2024 13:02:27 GMT<![CDATA[Reply to Embla Medical — December 2024 on Fri, 06 Dec 2024 07:58:53 GMT]]>Interview med Michael Friis som opsummerer 2024, hvor Embla aktien har leveret bedre end det generelle marked og MedTech https://proinvestor.com/boards/123346

]]>https://dev.proinvestor.com/forum/post/8056372https://dev.proinvestor.com/forum/post/8056372Fri, 06 Dec 2024 07:58:53 GMT<![CDATA[Reply to Embla Medical — December 2024 on Mon, 02 Dec 2024 09:47:59 GMT]]>Men på den anden side...Loftet på 36 giver nye investorer mulighed for at komme med på et rimeligt kursniveau.

]]>https://dev.proinvestor.com/forum/post/8056369https://dev.proinvestor.com/forum/post/8056369Mon, 02 Dec 2024 09:47:59 GMT<![CDATA[Reply to Embla Medical — December 2024 on Mon, 02 Dec 2024 09:45:50 GMT]]>Tak Helge... Det er jo væksten vi tålmodigt venter på. PS: Samt også på den korte bane, at sælgeren/sælgerne i området omkring slipper jerngrebet på kursen. 😉

]]>https://dev.proinvestor.com/forum/post/8056370https://dev.proinvestor.com/forum/post/8056370Mon, 02 Dec 2024 09:45:50 GMT<![CDATA[Reply to Embla Medical — December 2024 on Mon, 02 Dec 2024 09:30:54 GMT]]>Embla havde et ekspertkald på US Medicare reformen. Det er måske en øjenåbner for mange at mindre mobile patienter nu får adgang til bionics via tilskud - det vil hjælpe væksten over de næste 3-5 år, da det er den største ændring på tilskud de seneste 20 år. Se og lyt med her: https://player.cvm3.se/b3014e58-e983-49f1-9669-ae62f1113caa?fetch=true&embed=1

]]>https://dev.proinvestor.com/forum/post/8056373https://dev.proinvestor.com/forum/post/8056373Mon, 02 Dec 2024 09:30:54 GMT